KIDS GRAVOL LIQUID 15 MG / 5 ML
DIMENHYDRINATE : 15 MG / 5 ML · DIN 00230197 · CHURCH & DWIGHT CANADA CORP
Health Canada status: MARKETED
What is KIDS GRAVOL LIQUID?
KIDS GRAVOL LIQUID 15 MG / 5 ML contains DIMENHYDRINATE : 15 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 00230197, held by CHURCH & DWIGHT CANADA CORP, supplied as SYRUP for ORAL administration. Health Canada currently lists it as marketed, status dated 18-May-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is KIDS GRAVOL LIQUID used for?
Prevention and relief of nausea, vomiting and/or vertigo associated with motion sickness, radiation sickness, postoperative recovery, drug-induced nausea, and Meniere’s disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00230197 |
|---|---|
| Brand name | KIDS GRAVOL LIQUID |
| Generic / active ingredient | DIMENHYDRINATE : 15 MG / 5 ML |
| Manufacturer | CHURCH & DWIGHT CANADA CORP |
| Strength | 15 MG / 5 ML |
| Dosage form | SYRUP |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | R06AA11 DIMENHYDRINATE |
| AHFS class | 56:22.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-May-2021 |
| Original market date | 1951-12-31 00:00:00 |
How is it administered?
Adults: 50-100 mg every 4-6 hours (max 400 mg/24h). Children: Dose varies by age (2-12 years). IM/IV: 50-100 mg. IV must be diluted 1:10 and injected slowly.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at controlled room temperature (15°C – 30°C). Protect IM injection from freezing. Diluted IV solutions stable for 24 hours at room temperature.
How is it supplied?
Not explicitly detailed by pack size (e.g. "bottles of 100"), but lists various forms including vials, caplets, capsules, liquid, suppositories, and tablets.
Contraindications
Hypersensitivity to dimenhydrinate; MAO inhibitor therapy; narrow angle glaucoma; chronic lung disease; prostatic hypertrophy; children under 2 years of age.
Warnings and precautions
May impair mental alertness (driving/machinery). Abuse potential (hallucinogenic effects). Use caution in cardiac arrhythmias, seizure disorders, and patients with phenylketonuria (aspartame).
Is DIMENHYDRINATE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code R06AA11 DIMENHYDRINATE. 20 of 70 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ANTI-NAUSEANT | 50 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02241532 |
| ANTI-NAUSEANT LIQUID GELS | 50 MG | CAPSULE | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02493004 |
| CONFAB DIMENHYDRINATE 100 MG | 100 MG | SUPPOSITORY | LABORATOIRES CONFAB INC | MARKETED | DIN 00392545 |
| CONFAB DIMENHYDRINATE 50 MG | 50 MG | SUPPOSITORY | LABORATOIRES CONFAB INC | MARKETED | DIN 00392553 |
| DIMENHYDRINATE INJECTION USP | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00392731 |
| DIMENHYDRINATE INJECTION USP | 250 MG / 5 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02435241 |
| DIMENHYDRINATE INJECTION USP | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00392537 |
| DIMENHYDRINATE INJECTION USP | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02536536 |
| DIMENHYDRINATE INJECTION USP | 50 MG / 1 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02428954 |
| GAVISCON NAUSEA | 50 MG | TABLET | MEDTECH PRODUCTS INC | MARKETED | DIN 02490528 |
Who else supplies DIMENHYDRINATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DIMENHYDRINATE appears in 8 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.